Journal of Clinical Oncology, Vol 15, 2449-2455, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma

JA McCaffrey, S Hilton, M Mazumdar, S Sadan, M Heineman, J Hirsch, WK Kelly, HI Scher and DF Bajorin
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

PURPOSE: A phase II randomized trial of gallium nitrate/fluorouracil (5- FU) versus dose-intense methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) was performed in poor-risk patients with advanced urothelial tract tumors. The efficacy and toxicity of these regimens were compared. Assessment of dose-intense M-VAC as salvage treatment in patients who failed to respond to the gallium nitrate/5-FU regimen was also performed. PATIENTS AND METHODS: Thirty-four patients who had not received prior systemic chemotherapy were randomized to either arm of the study. All patients had one or more clinical features predicting a low likelihood of durable complete response to standard chemotherapy, ie, weight loss, visceral metastases, and low performance status. Gallium nitrate and 5-FU were each administered by continuous 5-day infusions every 28 days. M-VAC was recycled every 21 days, with prophylactic recombinant human granulocyte colony-stimulating factor (rh-G-CSF). RESULTS: Two of 17 patients (12%; 95% confidence interval [CI], 1.4% to 36.4%) had a major response to gallium nitrate/5-FU. Sixteen of 17 patients treated with M-VAC (94%; 95% CI, 71.3% to 99.8%) demonstrated a major response. Five of 12 patients who failed to respond to the gallium nitrate/5-FU combination responded to M-VAC as second-line therapy (42%; 95% CI, 15.2% to 72.3%). Median survival for the gallium nitrate and 5-FU arm was 19 versus 17 months for the M-VAC arm, with a median follow-up duration of 35 months (range, 2 to 51) for all patients. Dose-intense M-VAC was associated with a greater incidence of neutropenia and thrombocytopenia. CONCLUSION: Dose-intense M-VAC is superior to gallium nitrate/5-FU in poor-risk patients (P < .0001). Despite the overall high response rate, the median survival for patients with M-VAC remained unsatisfactory. Similar survival distributions were observed for patients who received investigational therapy followed by cisplatin-based therapy and patients treated with initial cisplatin-based therapy.

This article has been cited by other articles:

				F. Perabo and S. Muller New agents for treatment of advanced transitional cell carcinoma Ann. Onc., May 1, 2007; 18(5): 835 - 843. [Abstract] [Full Text] [PDF]

				G. Di Lorenzo, R. Autorino, A. Giordano, M. Giuliano, M. D'Armiento, A. R. Bianco, and S. De Placido FOLFOX-4 in Pre-treated Patients with Advanced Transitional Cell Carcinoma of the Bladder Jpn. J. Clin. Oncol., December 1, 2004; 34(12): 747 - 750. [Abstract] [Full Text] [PDF]

				D. Pectasides, J. Glotsos, N. Bountouroglou, A. Kouloubinis, N. Mitakidis, N. Karvounis, N. Ziras, and A. Athanassiou Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial Ann. Onc., February 20, 2002; 13(2): 243 - 250. [Abstract] [Full Text] [PDF]

				C. N. Sternberg, P. H.M. de Mulder, J. H. Schornagel, C. Theodore, S. D. Fossa, A. T. van Oosterom, F. Witjes, M. Spina, C. J. van Groeningen, C. de Balincourt, et al. Randomized Phase III Trial of High-Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924 J. Clin. Oncol., May 15, 2001; 19(10): 2638 - 2646. [Abstract] [Full Text] [PDF]

				F. K. Matzkies, B. Tombach, M. Dietrich, K. Kisters, M. Barenbrock, R. M. Schaefer, W. E. Berdel, and K. H. Rahn MVAC-therapy for advanced urothelial carcinoma in an anuric renal transplant recipient Nephrol. Dial. Transplant., January 1, 2000; 15(1): 110 - 112. [Full Text] [PDF]

				D. F. Bajorin, P. M. Dodd, M. Mazumdar, M. Fazzari, J. A. McCaffrey, H. I. Scher, H. Herr, G. Higgins, and M. G. Boyle Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy J. Clin. Oncol., October 1, 1999; 17(10): 3173 - 3181. [Abstract] [Full Text] [PDF]

				P. M. Dodd, J. A. McCaffrey, H. Herr, M. Mazumdar, J. Bacik, G. Higgins, M. G. Boyle, H. I. Scher, and D. F. Bajorin Outcome of Postchemotherapy Surgery After Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Unresectable or Metastatic Transitional Cell Carcinoma J. Clin. Oncol., August 1, 1999; 17(8): 2546 - 2546. [Abstract] [Full Text] [PDF]